Interpretation of the latest medical insurance inclusion policy for serputinib/serpatinib

Selpercatinib is a first-line targeted drug targeting RET-driven tumors. Since its approval in Europe, the United States and Japan, it has received widespread attention for its targeted efficacy in RET fusion or mutation-positive non-small cell lung cancer (NSCLC) and thyroid cancer. Domestically, the National Medical Products Administration (NMPA) approved the indications and marketing registration of seputinib in China as early as 2022, which means that it has legal prescription and access to clinical use.

However, "marketing" and "medical insurance accessibility" of drugsare two different paths. So far, although Seputinib has been approved for marketing in China, it has not been uniformly included in the national basic medical insurance (National Medical Insurance Directory) system. Patients still have to pay for the drug through conventional channels at their own expense or rely on commercial insurance and corporate/charitable assistance programs to relieve cost pressure. Different provinces, cities and regions have different local subsidies or temporary assistance programs for imported innovative anti-cancer drugs. Some local medical insurance or social security alternative programs may also reimburse part of the costs. However, this type of support is not a unified policy across the country. Patients need to consult local medical insurance or hospital pharmaceutical departments for specific feasibility.

Genetic testing, treatment availability, patient affordability, and alternatives (such as other covered treatments or clinical trials) should be discussed when making treatment decisions for RET-positive patients. For patients, knowing whether a drug is included in medical insurance, whether there is a manufacturer assistance program, and whether local medical insurance has temporary subsidies are key steps in determining the feasibility of treatment.

In short, serputinib has completed drug registration in China and can be used in prescription form, but medical insurance accessibility is still in the dynamic process of negotiation and local policy adjustments. Patients and doctors should pay close attention to official releases and patient support information from pharmaceutical companies.

Reference:https://en.wikipedia.org/wiki/Selpercatinib